Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-12 Engineered TILs in Metastatic Melanoma
NCT01236573Phase 2Terminated
- Sponsor
- National Institutes of Health
- Start
- Oct 2010
- Primary completion
- Mar 2015
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of IL-12 transduced TIL in melanoma (11 arms), sponsored by National Institutes of Health. Primary endpoints: Maximum Tolerated Dose at 4 years and Objective Response Rate at 4 years. Started Oct 2010; status: terminated.
02
Drugs
IL-12 transduced TIL
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01236573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01236573.